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OBJECTIVES: Bladder cancer represents 3% of all carcinomas in the Brazilian population and ranks second in
incidence among urological tumors, after prostate cancer. The loss of p53 function is the main genetic
alteration related to the development of high-grade muscle-invasive disease. Prima-1 is a small molecule that
restores tumor suppressor function to mutant p53 and induces cancer cell death in various cancer types. Our
aim was to investigate the ability of Prima-1 to induce apoptosis after DNA damage in bladder cancer cell lines.
METHOD: The therapeutic effect of Prima-1 was studied in two bladder cancer cell lines: T24, which is
characterized by a p53 mutation, and RT4, which is the wild-type for the p53 gene. Morphological features of
apoptosis induced by p53, including mitochondrial membrane potential changes and the expression of thirteen
genes involved in apoptosis, were assessed by microscopic observation and quantitative real-time PCR (qRT-
PCR).
RESULTS: Prima-1 was able to reactivate p53 function in the T24 (p53 mt) bladder cancer cell line and promote
apoptosis via the induction of Bax and Puma expression, activation of the caspase cascade and disruption of the
mitochondrial membrane in a BAK-independent manner.
CONCLUSION: Prima-1 is able to restore the transcriptional activity of p53. Experimental studies in vivo may be
conducted to test this molecule as a new therapeutic agent for urothelial carcinomas of the bladder, which
characteristically harbor p53 mutations.
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& INTRODUCTION
Bladder cancer (BC) represents 3% of all carcinomas in the
Brazilian male population and ranks second in incidence
among urological tumors, after prostate cancer (1), with
73,310 new cases and 14,880 deaths estimated for 2012 in the
USA (2).
Tobacco smoking, occupational exposure to aromatic
amines, arsenic, radiation exposure from the radiation
therapy of neighboring organs and the therapeutic use of
alkylating agents are the main risk factors for the develop-
ment of urothelial tumors (3).
A large number of genetic changes have been associated
with the genesis and progression of BC, and many of them
appear to abrogate the G1/S cell cycle checkpoint (4). In
particular, p53 loss of function has been related to the
development of high-grade muscle-invasive disease (5).
As a key gatekeeper of the G1/S checkpoint for cell-cycle
progression, p53 is indispensable for maintaining genomic
stability and keeping urothelial growth in check. Structural
and functional p53 defects are found in over one-half of
human urothelial carcinomas, contributing to genomic
instability and consequently, numerous chromosomal aber-
rations. p53 mutations first affect one allele, followed by a
second that may be a mutation, deletion or silencing by
methylation of the additional wild-type allele, which
disables the function of this tumor suppressor gene (6).
Consistent with this action, the expression of p21 (WAF1),
an important p53 downstream target, is downregulated in
the majority of urothelial carcinomas that harbor p53
mutations (7). Several codons in the p53 gene appear to be
preferentially mutated, including codons 280 and 285 (8).
The specific mutation of these codons is rare in other
epithelial tumors; thus, it has been suggested that they
result from a urothelium-specific carcinogen or carcinogenic
event.
Prima-1 (p53 reactivation and induction of massive
apoptosis 1) is a low–molecular weight compound identified
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in a cell-based chemical library screen at the National Cancer
Institute (National Institutes of Health, Bethesda, MD). This
compound has been demonstrated to suppress the growth of
cells that harbor mutant p53 by restoring the sequence-
specific DNA-binding, wild-type conformation and tran-
scriptional transactivation of mutant p53. Prima-1 has been
shown to induce apoptosis in human tumor cells in a p53-
dependent manner and suppress the growth of human tumor
xenografts carrying mutant p53 (9).
In this study, we examined the effects of Prima-1 on the
T24 and RT4 BC cell lines, which express a mutant and wild-
type p53 gene, respectively, and analyzed whether this
compound was able to induce p53 activity after UVC
damage. To test this hypothesis, we evaluated whether
exposing p53 wild-type (RT4) and p53 mutant (T24) cells to
Prima-1 and ultraviolet radiation (UVC) alters the expres-
sion of p53 downstream genes that are related to apoptosis
induction.
& MATERIALS AND METHODS
Cell Lines and Treatment
The human urothelial carcinoma T24 (p53 mt) cell line
was kindly provided by Dr. Salvadori (Botucatu, Brazil).
RT4, a primary urothelial carcinoma bladder cell line from a
Caucasian (p53 wt) was purchased from EACC (Salisbury,
UK). The cell lines were cultured in McCoy’s medium
supplemented with 20% (v/v) heat-inactivated fetal bovine
serum (Sigma, St.Louis, MO, USA) under an atmosphere of
5% CO2 at 37 C˚. For the experiments, T24 and RT4 cells were
seeded in 25 cm2 tissue culture flasks and maintained at
37 C˚/5% CO2 overnight to allow the cells to adhere. On the
next day, the cells were exposed to 253.7 nm of UVC for 2 h
to induce DNA damage. UVC radiation causes specific
DNA lesions, and in addition to being a powerful tool for
scientific studies, it is a methodology that is easily
implemented in the laboratory because the majority of
germicidal lamps emit UVC light (10). After exposure, the
cells were treated with 50 mM Prima-1 (Sigma, St.Louis, MO,
USA) for 1 and 192 h.
RNA Isolation and cDNA Synthesis
Following the above experiment, total RNA was isolated with
the mirVanaTM Kit (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s instructions. As a control, we
used T24 and RT4 cell lines cultured in McCoy’s medium
supplemented with 20% (v/v) heat-inactivated fetal bovine
serum (Sigma, St. Louis, MO, USA) in a 5% CO2 atmosphere at
37 C˚. RNA concentrations were determined by measuring the
absorbance at 260/280 nm using a Nanodrop ND-1000
spectrophotometer (Thermo Scientific, Wilmington, Delaware,
USA). cDNA was generated using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA,
USA). Reactions were incubated at 25 C˚ for 10 min, followed by
37 C˚ for 120 min and 85 C˚ for 5 min. The cDNA was stored at
220 C˚ until use.
Quantitative Real-Time PCR (qRT-PCR) and Gene
Expression
The expression level of 13 genes (Table 1) was analyzed
by qRT-PCR using an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems). Target sequences were amplified in a
10 ml reaction containing 5 ml of TaqMan Universal PCR
Master Mix, 0.5 ml of a TaqMan Gene Expression Assay
(Applied Biosystems, Foster City, CA, USA) (primers and
probes, see Table I), 1 ml of cDNA and 3.5 ml of DNase-free
water. The PCR cycling conditions were as follows: 2 min at
50 C˚, 10 min at 95 C˚ and 40 cycles of 15 seconds at 95 C˚ and
1 min at 60 C˚. A TaqMan B2M (Applied Biosystems, Foster
City, CA, USA) (b2 microglobulin) Assay was used as an
endogenous control.
We used the DDCT method to calculate the relative
expression of the 13 target genes using the following
formula: DDCT = (CT of the target gene in T24 and RT4
cells after 1, 18 and 192 h after exposure to 50 mM Prima-1 –
the CT of the endogenous control under the same condi-
tions) – (CT of the target gene in T24 and RT4 cells without
Prima-1 treatment - CT of the endogenous control under the
same conditions). The gene expression fold change was
calculated as 2-DDCT.
Evaluation of the mitochondrial membrane
potential by DePsipher
The DePsipher Kit (Trevigen, Gaithersburg, MD, USA)
was used to measure the mitochondrial membrane potential
under a fluorescence microscope (11,12). T24 and RT4 cells
(26105/ml) were seeded in a 24 well plate 24 h prior to the
experiments. Then, the plate was exposed to 253.7 nm of
UVC for 2 h for the induction of DNA damage. Prima-1
(50 mM) was added, and 18 h later, the cells were washed
with PBS and detached from the cell culture wells with
trypsin. As a control, we used T24 and RT4 cell lines
exposed to UVC for 2 h in the absence of treatment. The
Table 1 - Assay identifiers (IDs) used for qRT-PCR.
Gene symbol Gene name Assays IDs
CASP2 caspase 2, apoptosis-related cysteine peptidase Hs00234982_m1
CASP3 caspase 3, apoptosis-related cysteine peptidase Hs00234385_m1
CASP7 caspase 7, apoptosis-related cysteine peptidase Hs00169152_m1
CASP9 caspase 9, apoptosis-related cysteine peptidase Hs00964603_m1
BBC3 (PUMA) BCL2 binding component 3 Hs00248075_m1
BAK1 BCL2-antagonist/killer 1 Hs00940249_m1
BAX BCL2-associated X protein Hs00180269_m1
MDM2 Mdm2 p53 binding protein homolog Hs01066930_m1
PMAIP1 (NOXA) phorbol-12-myristate-13-acetate-induced protein 1 Hs00382168_m1
B2M b2-microglobulin Hs99999907_m1
CDKN1A (p21) cyclin-dependent kinase inhibitor 1A (p21, Cip1) Hs00355782_m1
TP53 tumor protein p53 Hs01034249_m1
APAF1 apoptotic peptidase activating factor 1 Hs00559441_m1
CYC1 (cytochrome-c) cytochrome c-1 Hs00357717_m1
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cells were incubated in the dark with 5 mg/ml DePsipher
(5.59.6.69-tetrachloro-1.19.3.39-tetraethyl-benzimidazolyl car-
bocyanin iodide) solution for 30 min at 37 C˚, washed with
reaction buffer with stabilizer, placed on a glass slide and
covered with a glass coverslip. The stained cells were
observed under an inverted fluorescence microscope using
a fluorescein long-pass filter (fluorescein and rhodamine).
DePsipher visualizes the potential-dependent accumulation
in mitochondria, which is indicated by a fluorescence
emission shift from red (590 nm) to green (530 nm).
Apoptosis analysis
Following the conditions previously reported, the mor-
phological aspects of the cells were analyzed and photo-
graphed under a microscope.
Ethics
This project was submitted to the research ethics
committee of the Hospital das Clı´nicas da Faculdade de
Medicina da Universidade de Sa˜o Paulo and approved at
the August 5th, 2009 meeting (Protocol No. 0718/09).
& RESULTS
Gene Expression Profile
The gene expression profiles after Prima-1 exposure to
both cell lines are presented in Figure 1.
Prima-1 and Apoptosis
Pmaip 1 and Bbc3 are important genes induced by p53 that
transcribe Noxa and Puma, respectively, and are essential for
apoptosis induction. Noxa was found to be induced at 0 and
1 h in the T24 cells, while Noxa expression was detected at 1
and 18 h in the RT4 cells. Puma was not detected in RT4 cells
but was overexpressed in T24 cells at 18 h.
Bak and Bax oligomerize and alter the permeability of
mitochondrial membranes by facilitating the release of
cytochrome c to activate caspases. In our model, only Bax
was expressed by the T24 cells after 18 h, while Bak was not
expressed. However, Bak was expressed in the p53 wt RT4
cells, while Bax was not expressed.
Our analysis revealed that caspase 9, Apaf-1 and
cytochrome-c, which are involved in the activation of the
caspase cascade, were progressively overexpressed in the
RT4 cells; however, in the T24 cells, these genes were more
expressed at 0 h and upregulated at 1 h; an even greater
increase was observed at 18 h. Caspase 2 is considered an
orphan caspase and thought to be an additional initiating
caspase. We observed progressive caspase 2 overexpression
in the T24 and RT4 cells. An analysis of the effector caspases
7 and 3 also demonstrated a progressive upregulation in
both cell lines, with a peak at 18 h.
Prima-1 and p53 Activation
To demonstrate that the apoptosis induction was related
to the reestablishment of p53 transcriptional activation, we
evaluated the expression of MDM2 and p21, which are
important p53-regulated genes. We found that p21 was
expressed in RT4 cells at low levels compared with T24 cells
after Prima-1 treatment, and the same pattern of expression
was noted for MDM2.
An evaluation of p53 expression in cell lines exposed to
UVC and Prima-1 revealed that while p53 was over-
expressed immediately after exposure in the p53 wt RT4
cell line, the same expression level was detected after 18 h in
the p53 mt T24 cell line.
Evaluation of the Mitochondrial Membrane
Potential with DePsipher
In T24 cells treated with 50 mM Prima-1, there was a
disruption in the DYm that was similar to what was
observed in RT4 cells exposed to UVC. This result was
different from that found for T24 cells that did not exhibit a
disruption in DYm in the absence of Prima-1 (Figure 2).
Morphological analysis
After a 2 h of exposure to UVC radiation followed by 192 h
of 50 mM Prima-1 treatment, we observed similar morpholo-
gical changes in the T24 and RT4 cell lines (Figure 3).
& DISCUSSION
In this study, we showed that Prima-1 induces apoptosis
in a p53 mutant bladder cancer cell line by reestablishing
p53 transcriptional activity.
Noxa was induced at 0 and 1 h in T24 cells, while in RT4
cells, Noxa expression was detected at 1 and 18 h. Puma was
not detected in RT4 cells but was overexpressed in T24 cells at
18 h. Bak and Bax oligomerize, altering the permeability of the
mitochondrial membrane by facilitating the release of cyto-
chrome c and activating caspases. In our model, only Bax was
expressed by T24 cells after 18 h, and Bak was not expressed at
any time after treatment. In contrast, Bak was expressed by the
p53 wt RT4 cells, while Bax was not expressed. A recent study
showed that p53 participates in the intrinsic cell death pathway
via the induction of Bax, Puma and Noxa (13). Thus, we can
argue that in our model, in which T24 cells were exposed to
UVC and Prima-1, intrinsic apoptosis pathway induction was
promoted by the restoration of the p53 transcriptional function
and the induction of Noxa, Puma and Bax expression.
Noxa and Puma are proteins transcribed by Pmaip 1 and
Bbc3, respectively, which are important p53-induced genes
that are considered essential mediators of the apoptotic arm
of the p53 pathway (14,15).
In studies with knockout mice, some authors have
demonstrated that Puma plays an important role in p53-
mediated apoptosis in a wide range of cell types (15-17),
while in this model of apoptosis, the role of Noxa is
restricted to fibroblasts (18). The dramatic effect that the loss
of Puma has on the sensitivity of different cell types in
relation to p53-mediated cell death is particularly revealing
(16,19), indicating that Puma is a crucial mediator of
apoptosis in response to p53. Lomonosova et al. (20)
demonstrated that other BH3 proteins along with p53, such
as Puma, could overcome the dependence on Bax and Bak
in mediating cell death. Thus, an explanation for our data
may be that we observed the expression of Puma but not
Bax and that the isolated expression of Bak, which was
independent of Bax, is sufficient to induce apoptosis. In
contrast, in the p53 wt RT4 cell line, we observed the
occurrence of apoptosis independent of Puma expression. A
difference in the described mechanism of apoptosis induc-
tion in this cell line has been described for cisplatin, which,
along with the phosphorylation and stabilization of p53,
activates the expression of Fas, Puma and caspase-10 (21).
A critical event for apoptosome assembly is the release of
cytochrome c from the mitochondria, a step tightly
regulated by members of the B cell lymphoma 2 (Bcl-2)
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protein family (22). This family is comprised of three
subfamilies, depending on the number of Bcl-2 homolog
(BH) domains that they contain. The antiapoptotic sub-
family consists of members containing BH4 domains, and
Bcl-2 is the most well-known protein in this class. The two
other subfamilies are proapoptotic in nature, either lacking
the BH4 domain (Bax, Bak) or solely containing a BH3
domain (BH3-only). Once the BH3-only subfamily is
activated, the inhibitory effects of the antiapoptotic Bcl-2
protein family are overcome, enabling the oligomerization
of Bak-Bax within the mitochondrial outer membrane
(MOM). Our results demonstrated differences in the
involvement of Bak and Bax, and the former was shown
to participate in apoptosis in RT4 cells and the latter in T24
Figure 1 - Profile of MDM2, Puma, Bax, Noxa, Casp9, Casp7, Casp3, Casp2, p53, Apaf-1, p21 and cytochrome-c gene expression in T24
(p53 mt) and RT4 (p53 wt) cells after UVC radiation and treatment with Prima -1 for 1 and 18 h, compared with the control.
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cells. Alternative routes reported by others help us under-
stand these discrepant results. Lei et al. (23) showed that
gossypol, a natural polyphenolic compound found in cotton
seeds and used in infertility testing, is subsequently able to
induce mitochondrial membrane rupture to release cyto-
chrome c, and this effect is independent of Bax and Bak
activation. Green et al. (24) postulated the existence of two
alternative routes for cytochrome c release. The first is that
the activation and oligomerization of Bax interacts with
other mitochondrial membrane proteins, leading to release
of cytochrome-c, and the second involves the opening of
mitochondrial pores and a nonspecific release of cyto-
chrome-c. In an experimental study with bak-/-/bax-/- mice,
Claveria et al. (25) found that the occurrence of pro-
grammed cell death was preserved.
In a study published by Katrhyn et al. concerning
deconstructing p53 transcriptional networks in tumor
suppression, the lack of Bax and Puma was not sufficient
to diminish apoptosis in some cell types, which may explain
the occurrence of apoptosis in the RT4 cell line even in their
absence (13).
Caspase-9 is an initiator caspase and is thus involved in
the initiation of the proteolytic cascade, which is associated
with the intrinsic apoptosis pathway (26,27). Once activated,
caspase-9 cleaves and activates the effector caspases 3 and 7,
which are required for proteolysis and subsequent cell
death (28). Our analysis revealed the effective initiators of
apoptosis, i.e., caspase 9, apaf-1 and cytochrome-c, respon-
sible for the activation of the caspase cascade. We demon-
strated that there was an upregulation of these genes in the
p53 wt RT4 cell line and the p53 mt Prima-1-treated T24
cells. There was a peak in the expression of caspase-9 in the
T24 cell line after UVC radiation exposure, followed by a
gradual decrease in its expression levels, while in the RT4
cells, the peak occurred later. Our analysis showed that the
effectors caspases, caspase 7 and 3, progressively increased
in cell lines, with a peak at 18 h for both. These data suggest
that Prima 1 was able to effectively induce apoptosis in a
p53 mutant bladder cancer cell line.
Caspase 2, which is considered an orphan caspase, is
considered another initiating caspase. This protein is the
most evolutionarily conserved of all caspases (29), and
although there are numerous reports concerning the role of
caspase-2 in apoptosis, there is much controversy regarding
this protein, making it difficult to correctly place caspase-2
in the apoptotic cascade; hence, its role in apoptosis remains
unclear, making it the orphan of the caspase family.
Although caspase-2 shares some substrate specificity with
executioner caspases (30,31), in many ways, it is considered
an initiator caspase. Caspase-2 has been reported to cleave
the pro-apoptotic Bcl2 family member Bid (32). This action
is generally considered to be the mode through which
caspase-2 initiates apoptosis. We also observed progressive
caspase 2 overexpression in the T24 and RT4 cell lines,
confirming the data published by Shen et al. (2008), who
demonstrated that caspase 2 plays an important role in the
intrinsic apoptosis pathway mediated by p53 promoting the
translocation of Bax to the mitochondria, a key step for the
release of cytochrome c (33).
The loss of mitochondrial membrane potential in the T24
strain occurred after 18 h of treatment with Prima-1,
Figure 2 - DYm evaluation by DePsipher (A) RT4 cells exposed to UVC in the absence of Prima-1. (B) RT4 cells exposed to UVC and
treated with Prima-1 for 18 h. (C) T24 cells exposed to UVC in the absence of Prima-1. (D) T24 cells exposed to UVC and treated with
Prima-1 for 18 h.
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demonstrating that this mechanism is a direct target of this
compound and confirming the findings of Shen et al. (33).
The morphological features observed in the T24 and RT4
cell lines after 24 h of treatment with Prima-1 demonstrates
morphological changes, which became more pronounced
with increasing treatment time.
To demonstrate that apoptosis induction was related to
the reestablishment of p53 transcriptional activation, we
evaluated the expression of other important genes regulated
by p53: MDM2 and p21. We found that p21 was expressed
at lower levels in RT4 compared with T24 cells upon Prima-
1 treatment, and the same was observed for MDM2. These
results suggest that Prima-1 was able to restore p53 function
because after treating the T24 cells (p53 mt), we observed an
increase in the expression of p21 and MDM2, which are
important genes activated by p53. The gradual increase in
the expression of p21 after UVC radiation exposure and
subsequent Prima-1 treatment is further evidence for the
restoration of p53 because the activation of p53 induces the
expression of many proteins, including p21 (34). Messina et
al. studied the effect of Prima-1 in thyroid cancer cells and
also demonstrated an increase in p21 expression following
treatment with this compound (35).
In evaluating the p53 expression in cell lines exposed to
UVC and Prima-1, we found that p53 was overexpressed
immediately after treatment in the p53 wt RT4 cell line,
and the same level of expression was detected after 18 h in
p53 mt T24 cell line. However, the p53 expression level in
T24 cells after cell damage was significantly lower than
that found in RT4 cells. Our findings also revealed that
Prima-1 acts to increase the p53 mRNA levels in p53 wt
cell lines. The mechanism involved in this phenomenon
has not been previously reported and requires additional
study.
There are no data in the English literature demonstrating
Prima-1 activity in bladder cancer cell lines. p53 mutations
are highly associated with high-grade invasive urothelial
carcinomas, and it is well known that there is a lack of
suitable therapeutic options for these cases (36). The
possibility of restoring p53 activity may be of great interest,
and the possibility of using it intravesically is tempting. We
have previously reported a preliminary study evaluating
Prima-1 as a potential treatment in an in vivo model of
orthotopic urothelial carcinoma. Although this treatment
was not effective, there were no side effects, and more
studies are necessary to consider this compound as an
option in clinical practice (37).
In conclusion, we demonstrated that Prima-1 is able to
reactivate p53 function in p53-mutated bladder cancer cell
line by promoting apoptosis, inducing the expression of Bax
and Puma, activating the caspase cascade and disrupting
the mitochondrial membrane independent of Bak in the T24
cell line (p53 mt).
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